Aripiprazole

The current Abilify tablet and selected solution labels cover schizophrenia, acute manic/mixed episodes in bipolar I disorder (alone or with lithium/valproate), adjunctive treatment of adult major depressive disorder, pediatric autism-associated irritability and pediatric Tourette’s disorder. Age-specific dosing follows below. Adjunctive MDD treatment is not antidepressant monotherapy; autism irritability treatment does not establish treatment of core autism features. The selected Aurobindo ODT label omits adjunctive MDD, so do not assume every generic label carries every Abilify indication.

Maintena and Asimtufii are labeled for schizophrenia in adults and maintenance monotherapy of bipolar I disorder in adults. They are not labeled for pediatric autism/Tourette’s, adjunctive MDD or rapid treatment of acute agitation. This reference covers oral tablets, the specified solution/ODT, and these two aripiprazole depots. Aripiprazole lauroxil (Aristada/Initio), short-acting agitation injection and sensor-containing products are separate products outside this dosing scope; never substitute their injections or initiation plans.

Give oral tablets once daily, with or without food. Titrate to response and tolerability and periodically reassess continued need. Interaction adjustments may override the listed doses.

These are daily oral totals using the Abilify tablet/selected solution labels; use an appropriate low-strength formulation rather than dividing an unsuitable ODT. Reassess efficacy, growth/weight, sedation and abnormal movements.

Selected solution is 1 mg/mL. Its label allows equal-milligram tablet substitution only through 25 mg; a patient on a 30-mg tablet should receive 25 mg of solution because exposure differs. Measure with a calibrated device. Selected ODT doses match oral tablet doses for its labeled indications; dissolve on the tongue and swallow, with or without liquid. Use dry hands and peel a blister rather than pushing through foil; do not divide an ODT. Its aspartame/phenylalanine content matters in phenylketonuria.

First establish oral aripiprazole tolerability; fully assessing it may take up to 2 weeks. A professional injects IM into deltoid or gluteal muscle. Standard maintenance is 400 mg monthly, no sooner than 26 days after the last injection; adverse reactions may justify 300 mg monthly. Standard 1-day initiation is two separate-site 400-mg Maintena injections plus one oral 20-mg dose that day. Standard 14-day initiation is one 400-mg injection plus 14 consecutive days of oral aripiprazole 10–20 mg/day, or the current oral antipsychotic in an already stable patient known to tolerate aripiprazole. Metabolism/interactions may require a different initiation plan.

A professional injects IM into the GLUTEAL muscle only. Standard dose is 960 mg every 2 months (56 days); may reduce to 720 mg for adverse reactions. Standard 1-day initiation combines one Asimtufii 960-mg injection, one Maintena 400-mg injection in a separate gluteal/deltoid muscle, and one oral 20-mg dose. Standard 14-day initiation uses Asimtufii 960 mg plus oral aripiprazole 10–20 mg/day for 14 days, or the current antipsychotic for a stable patient known to tolerate aripiprazole. A patient receiving Maintena 400 mg can instead receive Asimtufii 960 mg at the next scheduled injection (second or later Maintena injection). Label permits administration up to 2 weeks before/after the scheduled 2-month point. CYP adjustments still apply.

Contact the injection service for late doses; do not add oral medication or “catch-up” injections independently. Maintena: if >5 weeks since the last injection when dose 2 or 3 is missed, restart with the labeled 1-day or 14-day initiation; for dose 4 or later the restart threshold is >6 weeks. Earlier late doses are given promptly according to section 2.3. Asimtufii: >8 and <14 weeks, give promptly and resume the schedule; >14 weeks requires labeled reinitiation. At boundary times and with interactions, the service should apply the exact product label.

Hypersensitivity to aripiprazole is the formal contraindication in these selected labels; reactions range from rash/urticaria to anaphylaxis. Dementia-related psychosis is unapproved and carries a boxed mortality warning, rather than being described here as a formal section-4 contraindication. Review formulation excipients and selected ODT phenylalanine.

All selected labels warn of increased death risk in older adults with dementia-related psychosis; aripiprazole is not approved for that use. Oral labels also carry the antidepressant-related suicidal-thoughts/behavior warning in children, adolescents and young adults, relevant to adjunctive depression treatment. Monitor clinical worsening and suicidality in all patients receiving antidepressant treatment and involve caregivers. Maintena/Asimtufii boxed warnings address dementia mortality; they do not establish an adjunctive MDD indication.

Akathisia/restlessness, nausea, constipation, insomnia, sedation and extrapyramidal symptoms are reported, with frequencies varying by indication and age. Weight gain is important for oral and depot treatment; depot injection-site pain can occur. Postmarketing reports include severe allergy and DRESS without a predictable frequency. Suspected overdose needs emergency supportive care, airway assessment and an ECG; QT prolongation warrants cardiac monitoring. Dialysis is unlikely to help because protein binding is high. Depot exposure cannot simply be withdrawn after administration.

For oral Abilify/selected solution, known CYP2D6 poor metabolism or a strong CYP2D6 OR CYP3A4 inhibitor generally uses half the usual dose; poor metabolism plus a strong CYP3A4 inhibitor, or both strong pathway inhibitors, uses one quarter. Strong CYP3A4 inducers generally require doubling over 1–2 weeks; restore/reduce appropriately when the interacting drug stops. The oral label explicitly directs using the adjunctive MDD regimen without this automatic adjustment; follow that specific regimen and tolerability rather than a generic rule. The selected ODT has its own adjustment table and omits MDD.

For interacting inhibitors/inducers used >14 days, use the selected initiation-specific table. Known CYP2D6 poor metabolism: 300 mg monthly. With 1-day initiation, a strong CYP2D6 OR CYP3A4 inhibitor gives 300 mg, while both inhibitor pathways or poor metabolism plus a CYP3A4 inhibitor requires avoiding that initiation plan. With 14-day initiation: a 400-mg regimen becomes 300 mg with one strong pathway inhibitor or 200 mg with both; a 300-mg regimen becomes 200 mg with one or 160 mg with both. Poor metabolism plus a CYP3A4 inhibitor uses 200 mg with the 14-day plan. The 200/160-mg doses require vial kits, not syringes. Avoid CYP3A4 inducers >14 days; reassess dose when inhibitors stop.

Known CYP2D6 poor metabolism uses 720 mg every 2 months; its 1-day initiation uses oral 20 mg plus Maintena 300 mg and Asimtufii 720 mg. For >14-day strong CYP2D6 OR CYP3A4 inhibition, a 960-mg regimen is reduced to 720 mg. Avoid use with both strong inhibitor pathways, with poor metabolism plus a CYP3A4 inhibitor, or with CYP3A4 inducers. Label does not supply every hypothetical reduced-dose combination; obtain product-specific review rather than inventing one. Shorter interacting courses also deserve clinical review even when the label specifies no dose modification for <14 days.

Antihypertensives can add hypotension; benzodiazepines can add sedation and orthostasis. Monitor and adjust clinically. Oral pharmacokinetic studies do not require automatic adjustment with lithium or valproate, but their combined adverse effects still need assessment. Medication reconciliation should include newly started antibiotics/antifungals, antidepressants and enzyme-inducing antiseizure medicines.

Available human pregnancy data have not established a major-birth-defect or miscarriage signal, but late-pregnancy antipsychotic exposure can cause neonatal extrapyramidal/withdrawal symptoms, respiratory or feeding problems. Balance treatment risks with relapse and untreated-illness risks; discuss the pregnancy registry and monitor exposed newborns. Aripiprazole enters milk and can substantially reduce milk supply, including absent postpartum supply. Monitor breastfed infants for dehydration and inadequate weight gain and arrange an individualized feeding/treatment plan.

Oral age-specific evidence is 13–17 for schizophrenia, 10–17 for bipolar mania, 6–17 for autism irritability and 6–18 for Tourette’s. Pediatric depression use is not established by these labels. Maintena/Asimtufii pediatric safety/effectiveness is unestablished. Older adults need cautious dose selection and fall/cardiovascular assessment; age alone does not mandate one numerical adjustment. Dementia psychosis remains unapproved with mortality/stroke risks.

The oral Abilify label requires no adjustment for Child-Pugh 5–15 hepatic impairment or GFR 15–90 mL/min. Do not extend those exact data ranges into an unsupported dialysis claim. CYP2D6 poor metabolism does require adjustments as described above. Depot population data are derived from oral studies/modeling rather than dedicated studies in every population; use their product-specific tables and clinical assessment.

The therapeutic mechanism is not fully established. Proposed activity combines partial agonism at dopamine D2 and serotonin 5-HT1A receptors with antagonism at 5-HT2A receptors. This pharmacology does not establish approval for every behavioral symptom or eliminate extrapyramidal/metabolic risk.

Oral tablet peak concentrations occur about 3–5 hours after administration. Aripiprazole and active dehydro-aripiprazole have mean oral half-lives about 75 and 94 hours; steady state takes about 14 days, and CYP2D6 poor metabolism prolongs parent-drug elimination. Both are >99% protein bound. Metabolism is mainly CYP2D6/CYP3A4; little unchanged drug leaves in urine. Depots prolong absorption and persistence, which is why product-specific initiation, missed-dose and interaction plans matter. Oral solution exposure differs at higher nominal doses.

Document indication and goals, medicines/CYP factors, baseline weight and metabolic status, blood-pressure/fall risk and movement symptoms. Follow weight, glucose and lipids; check glucose promptly for thirst/polyuria or other hyperglycemia symptoms. Reassess akathisia, tardive movements, sedation, swallowing, impulse-control behaviors and suicidality. CBC monitoring is targeted to low-count/prior drug-induced risk. For depots verify oral tolerability, exact product, injection site, initiation regimen, last-dose date and follow-up appointment.

Seek urgent help for suicidal thoughts/crisis, fever with rigidity/confusion, severe rash/swelling, fainting or marked hyperglycemia symptoms. Report new gambling/shopping/sexual/eating urges and abnormal movements promptly. Avoid hazardous activities until effects are known; avoid overheating/dehydration and discuss alcohol/CNS depressants. Do not stop or change treatment independently. Oral solution needs calibrated measurement; depot injections require a professional, and missed visits need a restart assessment.

Abilify 10 mg is a pink modified-rectangle A-008/10 tablet (NDC 59148-008-13, 30 tablets). Apotex solution is 1 mg/mL in a 150-mL amber bottle with calibrated cup (NDC 60505-0404-5). Selected Aurobindo 10-mg ODT is white/off-white circular A 10 (NDC 59651-514-30, 30 tablets). Maintena 400-mg dual-chamber kit is NDC 59148-072-80; Asimtufii 960 mg/3.2 mL prefilled-syringe kit is NDC 59148-114-80. These identify selected packages, not all generic appearances.

Abilify tablets: 2/5/10/15/20/30 mg. Selected solution: 1 mg/mL; selected ODT: 10/15 mg. Maintena: 300/400-mg single-dose vial or dual-chamber syringe kits for reconstitution and IM deltoid/gluteal administration. Asimtufii: ready suspension in 720 mg/2.4 mL or 960 mg/3.2 mL single-dose syringes, IM gluteal only. Lauroxil and short-acting products are outside this verified dosing scope and are not substitutes.

Abilify tablets: 25°C, excursions 15–30°C. Selected solution/ODT: 20–25°C; solution can be used for up to 6 months after opening, never beyond expiration. Maintena dual-chamber syringes: below 30°C, do not freeze, protect from light in original packaging; vial kits: 25°C, excursions 15–30°C. Follow kit-specific reconstitution/use timing, rather than storing a prepared syringe by the unopened-kit rule. Asimtufii: 25°C, excursions 15–30°C; professional preparation and immediate administration follow its instructions. Keep oral medicines and injection kits secure away from children.